Abstract: The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.

Abstract: The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.

Abstract: The present invention relates to a method for generating glucose-responsive beta cells.

Abstract: The present invention relates to a method for generating glucose-responsive beta cells.

Abstract: The present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm.

Abstract: The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.

Abstract: The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.

Abstract: The present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm.

Abstract: The present invention relates to a method for generating glucose-responsive beta cells.

Abstract: The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.

Abstract: Herein is disclosed a method for differentiation of cells into insulin-producing cells, a cell population enriched for insulin-producing ?-cells and the use of such a cell population for treatment of a metabolic disorder in an individual in need thereof. Also disclosed is a method for treating a metabolic disorder.

Abstract: The present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm.

Abstract: The present invention relates to a method to differentiate pluripotent stem cells to a primitive streak cell population, in a stepwise manner for further maturation to definitive endoderm.

Abstract: The present invention relates to a method to control differentiation of human pluripotent stem cells, including human balstocyst derived stem (hBS) cells and to obtain specific endoderm cells. In particular, present invention relates to the use of FGF2 as the key factor in a specific concentration to control differentiation of definitive endoderm cells derived from hPS cells to specific endoderm cells. The invention also provides methods of obtaining endoderm cells comprising the use of FGFR and activation of the MAPK signalling pathway.

Abstract: A method for obtaining a stable xeno-free hBS cell line, xeno-free hBS cell lines obtained according to said method and use thereof.

Abstract: The present invention relates to a culture system for and a method for propagation of human blastocyst-derived stem cells (hBS cells) upon enzymatic dissociation into a single cell suspension. The culture system for propagation of human blastocyst-derived stem (hBS) cells comprises i) human feeder cells at a density of at least 50,000 cells/cm2, ii) one or more dissociation agents for dissociation of hBS cell colonies into a single cell suspension, and iii) a supportive culture medium, which culture system makes it possible to propagate hBS cells by dissociation of hBS cell colonies into a single cell suspension at each consecutive passage for an extended time period, while maintaining the significant characteristics of hBS cells.

Abstract: The present invention relates to methods for obtaining endodermal progenitor cells and further differentiating these to hepatocyte-like cells. Knowledge about the cell composition prior to the initiation of terminal differentiation is used to select one of two different protocols and one of two type of intermediate progenitors depending on the purpose for which the resulting hepatocyte-like cells are needed. Protocol A of the present invention relates to differentiation of extraembryonic-resembling endodermal progenitor cells to hepatocyte-like cells and may be selected when yield and purity of the obtained hepatocyte-like cells is important. Protocol B of the present invention relates to differentiation of mesendodermal-resembling progenitor cells to hepatocyte-like cells and may be selected when quality of the obtained hepatocyte-like cells is important.

Abstract: The present invention concerns a method for the establishment of pluripotent human blastocyst-derived stem (BS) cell lines, stem cells obtained by the method, differentiation of these cells into differentiated cells, the differentiated cells, and the use of these differentiated cells in the preparation of medicaments. The undifferentiated pluripotent stem cells can be made to differentiate to a number of specialized cell types which can be utilized in the manufacture of medicaments for treating a number of conditions or pathologies involving degeneration of tissue, e.g., of the pancreas leading to, e.g., development of diabetes, or of the CNS (e.g., Alzheimer's, Parkinson's disease, etc.) or degeneration of the CNS caused by e.g., stroke or physical trauma.